A prospective two-year study of progestin given alone in postmenopausal women: effect on lipid and metabolic parameters
Article Abstract:
Promegestone, a powerful progestin without the side-effects of producing masculine characteristics, does not seem to change lipoprotein levels and other metabolic factors in menopausal women. The value of progestins is usually evaluated in the context of estrogen replacement therapy. Researchers analyzed the biochemical effect of promegestone alone in 11 early menopausal women over a period of two years. For 21 days in a given 28-day cycle, 12 women (the control group) took a placebo pill and 11 women took a daily dose of 500 micrograms of promegestone. The two groups did not differ with respect to HDL concentrations, plasma lipids, lipoproteins and apolipoproteins. In addition, blood pressure, anti-blood clotting activity, enzyme and protein activities remained the same for the duration of the study. Therefore, promegestone may be of therapeutic value during and after menopause. The appearance of future negative reactions in combination with estrogen replacement therapy seems doubtful.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
The effects of progestins on bone density and bone metabolism in postmenopausal women: A randomized controlled trial
Article Abstract:
A study was conducted to evaluate the action of progestins on bone metabolism in early menopausal women. The results suggest that estrogen remains the primary bone active agent in hormone therapy, while progestins have significantly less activity.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Postmenopausal hormone therapy increases use of health services: Experience from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]
Article Abstract:
Study is conducted to compare the utilization of health services and health care costs in a randomized hormone therapy trial. It is found that hormone therapy caused additional expenses on health care.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate
- Abstracts: Written clinic procedures enhance delivery of HIV 'prevention with positives' counseling in primary health care settings
- Abstracts: The efficacy of caries detection using three intraoral films under different processing conditions. Success of an alternative for interim management of irreversible pulpitis
- Abstracts: Collaborative analysis of alpha-Synuclein gene promoter variability and Parkinson disease. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency
- Abstracts: Rapidly progressive cervical cancer: the Connecticut experience. The role of ultrasound evaluation in the detection of early-stage epithelial cancer